 <h1>Asparlas Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>calaspargase pegol</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about calaspargase pegol. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Asparlas.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to calaspargase pegol: intravenous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, calaspargase pegol (the active ingredient contained in Asparlas) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking calaspargase pegol:</p><p>
<i>More common</i>
</p><ul>
<li>Bloating</li>
<li>chills</li>
<li>constipation</li>
<li>dark urine</li>
<li>difficulty breathing</li>
<li>fast heartbeat</li>
<li>fever</li>
<li>indigestion</li>
<li>loss of appetite</li>
<li>nausea</li>
<li>pain in the chest, groin, or legs, especially the calves</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>severe, sudden headache</li>
<li>slurred speech</li>
<li>sudden loss of coordination</li>
<li>sudden, severe weakness or numbness in the arm or leg</li>
<li>vision changes</li>
<li>vomiting</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bleeding gums</li>
<li>chest pain or discomfort</li>
<li>confusion</li>
<li>cough</li>
<li>coughing up blood</li>
<li>difficulty in swallowing</li>
<li>dilated neck veins</li>
<li>dizziness</li>
<li>extreme tiredness or weakness</li>
<li>fainting</li>
<li>slow or irregular heartbeat</li>
<li>headache</li>
<li>increased menstrual flow or vaginal bleeding</li>
<li>itching in the genital or other skin areas</li>
<li>lightheadedness</li>
<li>nosebleeds</li>
<li>paralysis</li>
<li>prolonged bleeding from cuts</li>
<li>rapid, shallow breathing</li>
<li>red or black, tarry stools</li>
<li>red or dark brown urine</li>
<li>scaling of the skin</li>
<li>sneezing</li>
<li>sore throat</li>
<li>swelling of the face, fingers, feet, or lower legs</li>
<li>tightness in the chest</li>
<li>weight gain</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of calaspargase pegol may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Diarrhea</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to calaspargase pegol: intravenous solution</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Abnormal clotting (e.g., activated partial thromboplastin time prolonged, blood fibrinogen decreased; diarrhea: colitis, diarrhea, enterocolitis, neutropenic colitis) (14%)</p>
<p><b>Common</b> (1% to 10%): Embolic/thrombotic events (e.g., device related thrombosis, disseminated intravascular coagulation, embolism, intracardiac thrombus, intracranial venous sinus thrombosis, pulmonary embolism, superior sagittal sinus thrombosis, thrombosis in device, venous thrombosis, venous thrombosis limb), hemorrhage (e.g., disseminated intravascular coagulation, epistaxis, hematoma, hemorrhage intracranial, melena, esophageal ulcer hemorrhage, small intestinal hemorrhage, upper GI hemorrhage)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Sepsis (e.g., bacterial sepsis, sepsis), fungal infection (e.g., fungal infection, hepatic infection fungal, respiratory tract infection fungal, splenic infection fungal, systemic candida)</p>
<p><b>Frequency not reported</b>: Immunogenicity<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Elevated transaminase (e.g., alanine aminotransferase increased, aspartate aminotransferase increased, transaminases increased) (52%), bilirubin increased (e.g., bilirubin conjugated increased, blood bilirubin increased) (20%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Dyspnea (e.g., hypoxia, respiratory failure), pneumonia (e.g., lung infection, pneumonia, pneumonitis)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Arrhythmia (e.g., atrioventricular block complete, sinus tachycardia, ventricular arrhythmia), cardiac failure (e.g., ejection fraction decreased, left ventricular dysfunction)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Pancreatitis (e.g., amylase increased, lipase increased, pancreatic necrosis, pancreatitis, pancreatitis relapsing) (18%)</p>
<p><b>Common</b> (1% to 10%): Diarrhea<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Asparlas (calaspargase pegol)." Servier, Boston, MA. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>How does Asparlas (calaspargase pegol-mknl) compare to Oncaspar (pegaspargase)?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Asparlas (calaspargase pegol)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: miscellaneous antineoplastics</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Asparlas &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Acute Lymphoblastic Leukemia</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to calaspargase pegol: intravenous solution</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Abnormal clotting (e.g., activated partial thromboplastin time prolonged, blood fibrinogen decreased; diarrhea: colitis, diarrhea, enterocolitis, neutropenic colitis) (14%)</p><p><b>Common</b> (1% to 10%): Embolic/thrombotic events (e.g., device related thrombosis, disseminated intravascular coagulation, embolism, intracardiac thrombus, intracranial venous sinus thrombosis, pulmonary embolism, superior sagittal sinus thrombosis, thrombosis in device, venous thrombosis, venous thrombosis limb), hemorrhage (e.g., disseminated intravascular coagulation, epistaxis, hematoma, hemorrhage intracranial, melena, esophageal ulcer hemorrhage, small intestinal hemorrhage, upper GI hemorrhage)<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Hypersensitivity<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Sepsis (e.g., bacterial sepsis, sepsis), fungal infection (e.g., fungal infection, hepatic infection fungal, respiratory tract infection fungal, splenic infection fungal, systemic candida)</p><p><b>Frequency not reported</b>: Immunogenicity<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Elevated transaminase (e.g., alanine aminotransferase increased, aspartate aminotransferase increased, transaminases increased) (52%), bilirubin increased (e.g., bilirubin conjugated increased, blood bilirubin increased) (20%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Dyspnea (e.g., hypoxia, respiratory failure), pneumonia (e.g., lung infection, pneumonia, pneumonitis)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Arrhythmia (e.g., atrioventricular block complete, sinus tachycardia, ventricular arrhythmia), cardiac failure (e.g., ejection fraction decreased, left ventricular dysfunction)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Pancreatitis (e.g., amylase increased, lipase increased, pancreatic necrosis, pancreatitis, pancreatitis relapsing) (18%)</p><p><b>Common</b> (1% to 10%): Diarrhea<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Asparlas (calaspargase pegol)." Servier, Boston, MA. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>How does Asparlas (calaspargase pegol-mknl) compare to Oncaspar (pegaspargase)?</li>
</ul><h2>More about Asparlas (calaspargase pegol)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: miscellaneous antineoplastics</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Asparlas &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Acute Lymphoblastic Leukemia</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>